血管紧张素转换酶2在新冠肺炎发病及治疗中的作用研究进展

Q4 Pharmacology, Toxicology and Pharmaceutics

中国药理学与毒理学杂志 Pub Date : 2020-01-01 DOI:10.3867/j.issn.1000-3002.2020.08.003

L. Yang, Q. He

{"title":"血管紧张素转换酶2在新冠肺炎发病及治疗中的作用研究进展","authors":"L. Yang, Q. He","doi":"10.3867/j.issn.1000-3002.2020.08.003","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome Coronavirus type 2 (SARS-CoV-2) infection leads to severe acute respiratory system diseases, and its clinical manifestations and pulmonary pathological features are similar to those of acute lung injury and acute respiratory distress syndrome. Angiotensin-converting enzyme (ACE) 2 was previously identified as a functional receptor for the SARS Coronavirus (SARS-CoV), but it was recently discovered that SARS-CoV-2 could also bind to ACE2 on the cell surface to infect cells, causing cytopathic and tissue immune damage. Human ACE2, a homologous of human ACE, is a new type of metallocarboxypeptidase, with many properties distinct from ACE. ACE2 plays a unique role in the renin-angiotensin system and is involved in maintaining normal lung function. Currently, no definite and effective treatment scheme has been found for patients with Coronavirus disease 2019 (COVID-19). ACE2, as a key factor in the pathological pathway of COVID-19, is of great significance in the clinical treatment of and drug development against COVID-19. © 2020 Chinese Journal of Pharmacology and Toxicology. All rights reserved.","PeriodicalId":10149,"journal":{"name":"中国药理学与毒理学杂志","volume":"34 1","pages":"575-583"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress in role of angiotensin-converting enzyme 2 in pathogenesis and treatment of COVID-19\",\"authors\":\"L. Yang, Q. He\",\"doi\":\"10.3867/j.issn.1000-3002.2020.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe acute respiratory syndrome Coronavirus type 2 (SARS-CoV-2) infection leads to severe acute respiratory system diseases, and its clinical manifestations and pulmonary pathological features are similar to those of acute lung injury and acute respiratory distress syndrome. Angiotensin-converting enzyme (ACE) 2 was previously identified as a functional receptor for the SARS Coronavirus (SARS-CoV), but it was recently discovered that SARS-CoV-2 could also bind to ACE2 on the cell surface to infect cells, causing cytopathic and tissue immune damage. Human ACE2, a homologous of human ACE, is a new type of metallocarboxypeptidase, with many properties distinct from ACE. ACE2 plays a unique role in the renin-angiotensin system and is involved in maintaining normal lung function. Currently, no definite and effective treatment scheme has been found for patients with Coronavirus disease 2019 (COVID-19). ACE2, as a key factor in the pathological pathway of COVID-19, is of great significance in the clinical treatment of and drug development against COVID-19. © 2020 Chinese Journal of Pharmacology and Toxicology. All rights reserved.\",\"PeriodicalId\":10149,\"journal\":{\"name\":\"中国药理学与毒理学杂志\",\"volume\":\"34 1\",\"pages\":\"575-583\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国药理学与毒理学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3867/j.issn.1000-3002.2020.08.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国药理学与毒理学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3867/j.issn.1000-3002.2020.08.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

冠状病毒2型(SARS-CoV-2)感染可导致严重的急性呼吸系统疾病，其临床表现和肺部病理特征与急性肺损伤和急性呼吸窘迫综合征相似。血管紧张素转换酶(ACE) 2之前被确定为SARS冠状病毒(SARS- cov)的功能受体，但最近发现SARS- cov -2也可以结合细胞表面的ACE2感染细胞，引起细胞病变和组织免疫损伤。ACE2是一种与ACE同源的新型金属羧肽酶，具有许多与ACE不同的特性。ACE2在肾素-血管紧张素系统中发挥着独特的作用，并参与维持正常的肺功能。目前，对2019冠状病毒病(COVID-19)患者尚无明确有效的治疗方案。ACE2作为COVID-19病理通路的关键因子，在COVID-19的临床治疗和药物开发中具有重要意义。©2020中国药理学与毒理学杂志。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research progress in role of angiotensin-converting enzyme 2 in pathogenesis and treatment of COVID-19

Severe acute respiratory syndrome Coronavirus type 2 (SARS-CoV-2) infection leads to severe acute respiratory system diseases, and its clinical manifestations and pulmonary pathological features are similar to those of acute lung injury and acute respiratory distress syndrome. Angiotensin-converting enzyme (ACE) 2 was previously identified as a functional receptor for the SARS Coronavirus (SARS-CoV), but it was recently discovered that SARS-CoV-2 could also bind to ACE2 on the cell surface to infect cells, causing cytopathic and tissue immune damage. Human ACE2, a homologous of human ACE, is a new type of metallocarboxypeptidase, with many properties distinct from ACE. ACE2 plays a unique role in the renin-angiotensin system and is involved in maintaining normal lung function. Currently, no definite and effective treatment scheme has been found for patients with Coronavirus disease 2019 (COVID-19). ACE2, as a key factor in the pathological pathway of COVID-19, is of great significance in the clinical treatment of and drug development against COVID-19. © 2020 Chinese Journal of Pharmacology and Toxicology. All rights reserved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国药理学与毒理学杂志 Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.20

自引率

0.00%

发文量

6787

期刊介绍： Chinese Journal of Pharmacology and Toxicology was first published in November 1986. As a journal of high academic value jointly edited by the Chinese Pharmacological Society, Chinese Society of Toxicology and the Academy of Military Medical Sciences (AMMS), it is a dominating one in China’s biomedicine, devoted to publication of research findings, reviews of special topic and new technologies and methods in every branch of experimental toxicology and pharmacology.